CTOs on the Move

Calysta Energy

www.calystaenergy.com

 
Calysta, Inc. (www.calysta.com), Menlo Park, CA, is an innovator in industrial products for food and energy security. Calysta has two business units. Calysta Nutrition is developing and commercializing FeedKind™ protein, a natural, safe, non-GMO sustainable ingredient for fish feed and other applications. FeedKind™ protein is approved for sale in the European Union. Calysta Energy is developing high value industrial and chemical products with cost and performance advantages over current processes.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Calysta Energy raised $48M on 02/02/2016

Similar Companies

Sage Rutty and Co

Sage Rutty and Co is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GPB Scientific

GPB Scientific is transforming the process of purifying and enriching cells for cell therapy production. Reliable cell recovery and expansion are fundamental to the successful scale up of CAR-T or any therapeutic cell manufacturing process. GPB has developed a high-throughput, automatable, microfluidic closed-system for leukapheresis sample preparation and downstream processing of cells for CAR-T and other cell therapy production. This breakthrough reduces cell losses and skill-intensive manual steps.

Calithera

Calithera is discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Tumor metabolism and tumor immunology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients. Our lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. We are currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors. In tumor immunology, our lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Our ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.

Telesis Bio Incorporated

Telesis Bio is empowering researchers to accelerate the creation of novel synthetic biology solutions to address some of humanity`s greatest challenges. With our breakthrough automation solutions for biological synthesis and expertise in DNA biology, we enable rapid, accurate, and reproducible writing of DNA and mRNA for wide-ranging biological applications. Around the world, innovators are leveraging Telesis Bio`s technology to overcome current bottlenecks in synthetic biology workflows and advance the discovery of cutting-edge solutions for health and technology. We are proud of our growing collaborations with partners that include premier academic research institutions, emerging start-ups to nearly all of the Top 25 Biopharma companies. Telesis Bio is honored to play a part in several pioneering advances of our customers and collaborators ranging from novel infectious disease vaccines, precision immunotherapy for cancer and antibody therapeutics to creation of engineered meat substitutes and sustainable cellular agricultural products.

BELPORT COMPANY INC

BELPORT COMPANY INC is a Camarillo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.